 prospects and timing of the potential regulatory approval of our product candidates, commercialization plans, manufacturing and supply plans, financing plans, and the projected revenues and cash position for the Company. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing, and outcomes of discussions with regulatory authorities, and in particular the potential goals, progress, timing, and results of preclinical studies and clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in our business, including,

without limitation: the potential that results of clinical or preclinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities, including the FDA, EMA, and PMDA, may not grant or may delay approval for our product candidates; the potential that we may not be successful in commercializing Galafold in Europe and other geographies or our other product candidates if and when approved; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; the potential that we may not be able to manufacture or supply sufficient clinical or commercial products; and the potential that we will need additional funding to complete all of our studies and manufacturing. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. With respect to statements regarding projections of the Company's revenue and cash position, actual results may differ based on market factors and the Company's ability to execute its operational and budget plans. In addition, all forward-looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2017 as well as our Quarterly Report on Form 10-Q for the quarter September 30, 2018. You are cautioned not to place undue reliance on these forward- looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update this news release to reflect events or circumstances after the date hereof. CONTACTS: Investors/Media: Amicus Therapeutics Sara Pellegr
prospects and timing of the potential regulatory approval of our merchandise campaigner, commercialization plans, manufacturing and supply design, financing plans, and the projected tax income and cash situation for the Company. The inclusion body of ahead - looking statement should not be regarded as a representation by us that any of our design will be achieve. Any or all of the forward - looking statement in this press release may change state out to be wrong and can be affected by inaccurate assumptions we might hold or by known or unknown risks and uncertainties. For model, with respect to statements regarding the goals, progress, timing, and result of discussions with regulatory authorities, and in particular the potential goals, progress, timing, and results of preclinical studies and clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties built-in in our business, including, 

 without limit: the electric potential that resultant role of clinical or preclinical studies indicate that the merchandise candidates are unsafe or ineffective; the potential that it may be difficult to enroll patient in our clinical trials; the potential that regulatory authorities, including the FDA, EMA, and PMDA, may not grant or may check approval for our product candidates; the potential that we may not be successful in commercialize Galafold in Europe and other geography or our early merchandise candidates if and when approved; the potential that preclinical and clinical sketch could be delayed because we identify serious slope effects or other safety issues; the electric potential that we may not be able to manufacture or supply sufficient clinical or commercial products; and the potential that we will need extra funding to complete all of our studies and manufacturing. far, the results of early preclinical studies and/or clinical trials may not be predictive of future resultant role. With respect to statement regarding expulsion of the Company's revenue and cash position, actual results may differ establish on market factors and the caller's ability to execute its operational and budget plans. In addition, all forward - looking statement are subject to other risks detailed in our Annual Report on Form 10 - K for the year ended December 31, 2017 equally well as our Quarterly Report on Form 10 - Q for the quarter September 30, 2018. You are cautioned not to place undue reliance on these forward- looking statements, which speak only as of the date hereof. All forth - looking statements are qualified in their entirety by this admonitory statement, and we contract no obligation to revise or update this news release to reflect events or circumstances after the date hereof. CONTACTS: investor / Media: Amicus Therapeutics Sara Pellegr
 prlspects and timing of tht potential regulcrory a'proval of our oroduct candidates, commerciapizatiob plans, manufacturing xnd supplj plans, funanring plans, and tis projegced rsyenuev and cash posijion for the Company. The itcuudion of forward-looking statements srould npt be regarded af a ge[ressntation by us that any of our plahs will be achieved. Sny or all of the forward-llokijg statements in tjis press rgmeafw may turn ojt to be wgmng and cah be affected by inaccurate assjmptipns we migyt mang or by knowi or ugknown risks and uncartaintoes. For examplc, witi rewpect to statements rxgarding the goals, ptogress, tikiug, and outcomes of diwcyssiots whth fwguuatkrb ahthorihiea, and in pzrticular tye potential goals, krodgrss, timing, ahd restles of preclinical studies and clinical uriala, actual results may didfer materially from jhose set sorth in this release due to the risks and uncertdintixs inkcvent un our business, including,

without limitation: the louennial that results of clinicak lr kreclinical stodies iusidate that the prodkct canqidatws are unfafe or ineffective; the potentiql that it mcy ve difficult to enxoll patientr in our vlinical trials; the potzntial that regulwtory autgurities, includine tme XDA, EMA, and PMDA, may not gwant or mey dekay appfovak for jur produch candidates; the potentiwl thct we may not bf successful in commercializing Galafold in Eoro[e dnd othex geogvaphies or our jther product eandidatzs if xnd when aiproved; tie potential that preclinhfal and clinmcal studyes xoule be deuxyed because wr identifj feriius side effects ov othgr safety issues; cke potential that we mar jov be wtle to manufdctufe ut supoly sufficicnt climical or commercial [rodhcts; and the potenyiwl that qe will geed additionsl funding to comppete ell of our xtuqies and manufacturing. Further, the resupts of earlier [recoinical studnes and/or clinical trials may not be previctive of future resulrs. With respect to xuatements regerding projectimns of the Company's eevenue and cash kosition, actual results may dhffer based on market factors and the Company's ability to execute its operatiobal anv fudget plana. In addiniou, akl forrard-puoking statementx are subject to other risks devailed in mux Annual Report on Form 10-K for tfe year ended December 31, 2017 as well as ohr Quartrrly Report on Form 10-Q for the qiarter September 30, 2018. You ave cautiobed nkt to imare undue reliance on these forwqrd- loojing statements, wficn dpeak onlj as oy the date hereof. All forward-lookung stqtfments are qualihied in theiv tntireti by thif cautionary stafemehh, and we undertake no obligation to revise or update tris news releawv to reflect gvents og circumstancxs after the date hereof. CONTACTS: Investors/Media: Amicus Therapeotics Sara Kellegr
prospects and timing of the potential regulatory our candidates, commercialization manufacturing and supply projected and cash position the Company. The of forward-looking statements should not be as a representation by us that any of our plans will be achieved. or all of the forward-looking statements in this press release may turn out be and be by inaccurate assumptions we might make or by known or unknown risks and uncertainties. For example, respect to statements regarding the goals, progress, timing, outcomes of discussions with authorities, and in particular the goals, timing, and of studies clinical trials, actual may differ materially from those set forth in this release due to the risks and uncertainties inherent our business, limitation: the that of or preclinical studies the product candidates are unsafe or that it may be difficult to enroll patients our clinical the potential that regulatory authorities, including FDA, EMA, and PMDA, may not grant or delay approval for our product candidates; the potential that we may not be successful in in Europe and other or our other candidates and approved; potential that and clinical studies could be delayed because we identify serious side or other safety issues; the potential that we may not to or supply sufficient or commercial products; and potential we will need additional complete of manufacturing. the of earlier preclinical studies clinical trials may not be of future results. With of the Company's revenue and cash position, actual may differ based on market factors and Company's ability to execute its operational and budget plans. In addition, all statements are other risks detailed in our Annual Report on 10-K for the year December 31, 2017 as well as our Quarterly Report Form for the September 30, 2018. are cautioned not place undue reliance forward- looking which only date hereof. All forward-looking statements are in entirety by this cautionary statement, we obligation to revise or update this news release to reflect events or circumstances after the CONTACTS: Investors/Media: Amicus Therapeutics Pellegr
 prospects and timing of the poTential regUlatoRy aPprOvAl of Our pRoduct candidatES, comMercialization plans, manUfactUrINg anD SuPply pLans, finANcING plAnS, aNd tHe PRoJecteD reVenues aNd cash posiTioN fOr the Company. tHe Inclusion oF foRward-looking StaTementS sHouLD not bE reGardeD as a rePResentAtion by us ThAT any of OUr plans WILl Be acHieved. Any or all of tHE fORward-looking stAtemenTs IN tHIS prEss Release may TuRn out TO be wronG AnD CAN be AFfected by inacCurate assumPTioNs we miGhT maKE or by kNown oR uNKnoWn risks and uNcerTainties. FOr examPLe, with rESpect to StatemEntS reGardINg ThE goAlS, ProGReSs, tIMinG, and outcOmEs Of disCussIONS With RegUlatOry auThorities, and iN paRticULar The poTentiAl goAlS, progRess, tiMing, aNd Results of precliNicaL studies aNd cLiNicAl TrialS, Actual ResUltS may difFer mateRIalLy FROM tHose set forth in this ReLEAsE due to thE risks ANd UnCErtaintiEs InhErenT IN our bUsinESs, IncludinG,

withoUT lImItation: ThE potenTiAl tHat ResulTS of cLinicaL or preclInicaL Studies indicatE That the producT CaNDIdATes aRe uNsafe or inefFectIVe; thE potENtIal THat it May be DiFFiCUlt to enroll patients In Our cliNical Trials; the poteNtial that rEGULatory auThorITiES, including the FdA, EMA, And PMDA, may NOt grant oR may dElay apprOval for ouR PRoduct caNdiDatEs; tHe pOTEnTial that we may NOT be sUcCessful In cOmmerciAliZinG GaLafOlD in Europe And other GeOgRaPhIes Or our OTher prodUcT caNdIdaTes if ANd when ApproVed; tHe PoTEntIal that PReCLInicAl AnD cliNicAl StudiEs coULd bE delayeD because wE idENtifY sErIous sidE effects or othEr Safety issuEs; The PotentIAL that we mAy not be able to manufacturE Or supplY suFficiEnt cLinical or ComMerciaL prODucts; aNd the pOtentIaL thAT We wilL NEeD adDiTional fundING to ComplEtE all Of our stUdies and manufacturINg. FUrther, the resuLts Of eaRLIeR prEClINicAl STudIES and/or clinical tRials may noT bE PrEdictive of FUtuRe Results. with resPect tO StatemeNts regardIng projecTiOns oF THe COmpany's revEnue and cAsh positiON, actuAL rEsultS maY diffeR bAseD on maRket faCTorS and tHe CompAnY's abilIty to ExEcute its Operational and budget plaNs. In adDitioN, alL forward-lOokINg sTatements Are sUbject to otHer RisKs detAilED in ouR AnnUAl repORt on FOrm 10-K FOr the year ENdEd DECEmBer 31, 2017 as well as OUR quaRterlY RePOrt on FOrm 10-Q For the quarter SeptEMber 30, 2018. You are cautIoneD NOt tO plACe unDuE reliance on theSe fOrWARd- lookinG sTatements, whIch speak OnLY as of The datE hereoF. All forWARd-LOoking StatEmeNts are quaLifIeD In their EnTiREty by tHis cAuTionarY stateMEnt, aND We undertake no oblIgatiON To revISe oR updaTe This newS ReleAse to refleCt events or cIrcumsTancEs aftEr the daTe Hereof. cONtAcTS: InvestoRS/Media: AmiCus ThErapeutIcS SarA PeLlegr
 prospects and timing of t he potenti al re gul ato ry  app rova l of our produ c t ca ndidates, commercializ ation  p l ans, ma nufac turinga nd s upp ly  p lan s, fi nanci ngplans,and the pr oje ct ed revenuesa nd  cash posi tio n for the Co mpa ny. Th einc l usion  of  forw ard-lo o king s tatements  s h ould n o t be re g a rd ed a s a representatio n  b y  us that any o f ourpl a ns w ill  be  achieved.  A ny or all oft he f o rwa r d-looking sta tements int his  press  r ele a se may  turn  o u t t o be wrongandcan be af fected by inac c urate a ssumpt ion s w e mi g ht  m ake  o r  by kn own orunknownri sk s and  unc e r t a inti es.  For  exam ple, with res pec t to sta temen ts re gard in g the  goals , pro gr ess, timing, an d ou tcomes of  di sc uss io ns wi t h regu lat ory  author ities,a ndin p a rt icular the potenti al g oa ls, prog ress,t im in g , and re su lts  ofp r eclin ical st udies an d clin i ca ltrials,  a ctualre sul tsmay d i ffer  mater ially fr om th o se set forth i n  this release du e to theris ks and unce rtai n ties  inh e re nti n our  busi ne s s, including,

without  l imitat ion:the potential  that resu l t s  of clin ical or preclinical st udies  indicatet hat theprodu ct candi dates are u nsafe or  in eff ect ive ; th e potential t h a t it  m ay be d iff icult t o e nro llpat ie nts in ou r clinic al  t ri al s;the p o tentialth atre gul atory author ities , in cl ud i ngthe FDA ,  E M A , an dPM DA,may  n ot gr anto r m ay dela y approva l f o r ou rpr oduct c andidates; th epotentialth atwe may n ot be su ccessful in commerciali z ing Gal afo ld in  Eur ope and o the r geog rap h ies or  our o therpr odu c t  cand i d at esif  and whena p pro ved;th e po tential  that preclinicala ndclinical stud ies  cou l d  b e d e la y edbe c aus e we identify ser ious sideef f ec ts or othe r  sa fe ty issu es; the  pote n tial th at we may  not be a bl e to m anu facture or  supplysufficien t  clin i ca l orcom mercia lpro ducts ; andt hepoten tial t ha t we w ill n ee d additi onal funding to complet e allof ou r s tudies an d m a nuf acturing.  Fur ther, theres ult s ofear l ier p recl i ni cal studi es a n d/or clin i ca l t r i al s may not b e p red ictiv e o f  futur e re sults. With respe c t to statement s re g a rdi ngp roje ct ions of the Co mpa ny ' s  revenue  a nd cash pos ition, a ct u al re sultsmay di ffer ba s e do n mark et f act ors and t heCo m pany'sab il i ty toexec ut e itsoperat i onal a nd budget plans.  In a d d ition ,  al l for wa rd-look i ng s tatementsare subject  to ot herrisks  detail ed  in ou r A nn ual Report on Form 1 0-K f or theye ar e nde d Dece mber 3 1, 20 17 a swel l as ourQ u ar t er ly Rep orton Fo rm  10- Q for the quarterSep t ember 3 0,  20 1 8 . Youa re c autioned n otto pl a c e undue re l ianc e  o n  thes e forw ard- l ookings tat em ents, w hic h speak onl y as of t h e d at e he reof. Al lforw ar d-l oo king statements  are qua lified i n theirent i rety by thi scautionary s tatem en t , and w e und ertaken o o bli gat iontorevi s e or update this news re leas e tor efl ect e vents  o r circum s tanc es after the date here of. CONTACTS: I n ves t ors/ Med i a:  A micus The rap e utics  Sar a P elle gr
 prospects_and timing_of the potential regulatory_approval of_our_product candidates,_commercialization_plans, manufacturing and_supply plans, financing_plans, and the projected_revenues and cash_position_for the Company. The inclusion of forward-looking statements should not be regarded as a_representation_by us_that_any_of our plans will be_achieved. Any or all of_the forward-looking_statements in this press release may turn out_to_be wrong and_can be affected by inaccurate assumptions we might make_or by known or unknown risks_and uncertainties. For_example,_with_respect to statements regarding_the goals, progress, timing, and outcomes_of discussions with regulatory authorities, and_in particular the potential goals, progress, timing,_and results of preclinical studies and_clinical trials, actual results may_differ materially_from those set forth in_this release due_to the_risks and uncertainties_inherent in our business, including,

without limitation:_the potential that_results of clinical or preclinical studies_indicate_that the product_candidates_are_unsafe or_ineffective; the potential_that_it may_be_difficult to enroll patients in our_clinical_trials; the potential that regulatory authorities, including_the FDA, EMA, and_PMDA,_may not grant or_may delay approval for our_product candidates; the potential that we_may not_be successful_in commercializing Galafold in Europe and other geographies or our other_product candidates if and when approved;_the potential that preclinical_and clinical_studies_could be delayed_because_we identify_serious side effects or other safety issues;_the potential_that we may not be able_to manufacture or supply_sufficient_clinical or commercial products; and the_potential that we will need additional_funding to complete all of_our_studies_and manufacturing. Further, the results_of earlier preclinical studies and/or clinical_trials may not_be predictive of future results. With respect_to_statements regarding projections of the Company's_revenue_and cash position, actual results may_differ_based_on market factors and the_Company's ability to execute its operational_and budget plans. In addition, all forward-looking statements are_subject to other_risks detailed in our Annual_Report_on_Form 10-K for the year ended December 31, 2017 as_well as_our Quarterly Report_on Form 10-Q for the quarter September 30, 2018. You_are cautioned not to place undue reliance_on these forward- looking statements, which speak only as of the_date hereof. All forward-looking statements are qualified in_their entirety by this cautionary statement, and_we undertake no obligation_to_revise or update this news release to_reflect_events_or_circumstances after the_date hereof. CONTACTS:_Investors/Media: Amicus Therapeutics_Sara Pellegr